コーパス検索結果 (left1)
通し番号をクリックするとPubMedの該当ページを表示します
1 BWS is thought to involve one or more imprinted genes, s
2 BWS patients enrolled onto NWTS 4 had smaller tumors tha
3 BWS patients were more likely to present with lower-stag
4 though SSCP analysis of 62 WT samples and 10 BWS patients did not result in the identification of any
6 II (IGF2), which was found in 2 of 10 (20%) BWS patients, even though LOI of IGF2 occurs frequently
8 ese associations were still significant in a BWS subgroup with KvDMR1 LOM, suggesting that the G alle
11 amine their expression pattern in tumors and BWS patients, since epigenetic alteration at these loci
16 ix of 149 cases were reported from a British BWS registry; the same numbers were recorded in a French
18 en inherited maternally, the deletion causes BWS with silencing of p57(KIP2), indicating deletion of
19 lated, genes, we generated a mouse model for BWS that both harbors a null mutation in p57(Kip2) and d
20 ) mice provide an important animal model for BWS, as well as sporadic cancers associated with it, inc
21 hway and is responsible at least in part for BWS-associated tumorigenesis as well as sporadic human c
29 most common constitutional abnormalities in BWS are epigenetic, involving abnormal methylation of ei
31 P2), alterations in which are more common in BWS, and a more telomeric domain including IGF2, alterat
32 s, translocations, or methylation defects in BWS have so far been found in three of the linked matern
33 S; however, a role of TGF-beta deficiency in BWS-associated neoplastic transformation is unexplored.
38 in conformations are differently favoured in BWS and SRS likely predisposing the locus to the activat
39 ions and CTCF--cohesin binding at the ICR in BWS and SRS together with DNA methylation correlate with
40 ated by CTCF, and this regulation is lost in BWS, leading to aberrant overexpression of growth-promot
41 t the hypothesis that loss of methylation in BWS patients activates the repressive function of KvDMR1
42 many phenotypic characteristics observed in BWS patients, suggesting that beta2SP mutant mice phenoc
43 g of the IGF2 gene is frequently observed in BWS, as is reduced CDKN1C expression related to loss of
45 s disrupted by chromosomal rearrangements in BWS patients, as well as by a balanced chromosomal trans
47 ine an epigenotype-phenotype relationship in BWS, in which aberrant methylation of H19 and LIT1 and U
53 and characterized a mouse model that mimics BWS microdeletions to define the role of the deleted seq
54 st within the KvLQT1 locus, because multiple BWS-associated chromosome rearrangements disrupt this ge
60 ific expression and/or methylation in 20% of BWS patients, and p57KIP2, a cyclin-dependent kinase inh
61 st or lymphocyte DNA; whereas, in 4 cases of BWS with H19 hypermethylation, methylation at KvDMRl was
64 mice display many of the characteristics of BWS, including placentomegaly and dysplasia, kidney dysp
69 c characteristics of the most common form of BWS, including loss of methylation at KvDMR1 and biallel
71 ollow muscle development in a mouse model of BWS to dissect the separate and shared roles for misexpr
72 al characteristics and treatment outcomes of BWS patients compared with patients with WT without BWS.
73 addition, the precise phenotypic spectrum of BWS might depend on which maternally expressed gene is m
78 uggesting that beta2SP mutant mice phenocopy BWS, and beta2SP loss could be one of the mechanisms ass
79 hat the maternal allele is disrupted in rare BWS patients with balanced germ-line chromosomal rearran
84 rchitecture of IC2 in patients with sporadic BWS caused by isolated LOM to identify conserved feature
87 associated with Beckwith-Wiedemann syndrome (BWS) and Silver-Russell syndrome (SRS), depending on the
90 in the region, Beckwith-Wiedemann syndrome (BWS) and Wilms tumor are each associated with loss of ma
92 Children with Beckwith-Wiedemann syndrome (BWS) are at increased risk for developing Wilms' tumor (
93 m patients with Beckwith-Wiedemann syndrome (BWS) have been mapped to 11p15.5 between p57KIP2 and IGF
106 drome (PWS) and Beckwith-Wiedemann Syndrome (BWS) where imprinting is known to be a contributing fact
107 m patients with Beckwith-Wiedemann syndrome (BWS), a condition characterized by prenatal overgrowth a
108 ases, including Beckwith-Wiedemann syndrome (BWS), a disorder of prenatal overgrowth and predispositi
109 s with sporadic Beckwith-Wiedemann syndrome (BWS), a fetal overgrowth syndrome associated with an imp
110 features of the Beckwith-Wiedemann syndrome (BWS), a genetically complex human disorder associated wi
111 inting leads to Beckwith-Wiedemann syndrome (BWS), an overgrowth and cancer predisposition condition.
114 tal disorder is Beckwith-Wiedemann syndrome (BWS), which increases risk for embryonal cancers, includ
116 f patients with Beckwith-Wiedemann syndrome (BWS), which predisposes to WT and also involves LOI of I
126 ith chromosomal rearrangements, suggest that BWS can involve disruption of multiple independent 11p15
131 K9me3 and H4K20me3 becoming biallelic in the BWS and H3K4me2, H3K27me3 and H3K9ac together with CTCF-
137 screen for other genetic predispositions to BWS, the conserved sequences between human and mouse dif
142 The only known mutations associated with BWS are maternally transmitted translocations, which are
143 ional epigenetic alterations associated with BWS have been well characterized and include epigenetic
147 -beta signaling, is causally associated with BWS; however, a role of TGF-beta deficiency in BWS-assoc
148 We analyzed a cohort of 52 children with BWS and UPD using a panel of microsatellite markers for
151 Like children without BWS, children with BWS and WT have an excellent prognosis with modern treat
157 The cohort consisted of 92 patients with BWS and molecular analysis of both H19 and LIT1, and the
159 t, and that in the majority of patients with BWS, LIT1 is abnormally expressed from both the paternal
162 ients were nearly identical to those without BWS, with overall survival at 4 years from diagnosis at